ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer

Mol Cell Oncol. 2018 Oct 9;5(6):e1526005. doi: 10.1080/23723556.2018.1526005. eCollection 2018.

Abstract

Estrogen receptor alpha gene (ESR1) fusion transcripts have been identified in breast cancer but their role in breast cancer is not completely understood. Here, we report a causal role for ESR1 fusions in driving both endocrine therapy resistance and metastasis, and describe a therapeutic strategy to target ESR1 fusion-induced growth.

Keywords: EMT; ESR1 fusions; breast cancer; endocrine therapy resistance; metastasis.